Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000051 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag for Post Transplant Thrombocytopenia
A Phase 2 study of Thrombocytopenia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01000051 is a Phase 2 study of Thrombocytopenia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants, below the 309-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01000051, a Phase 2 study of Thrombocytopenia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eltrombopag
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-02-17 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000051
The ClinicalTrials.gov registry entry for NCT01000051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 309-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (79% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01000051 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01000051 about?
NCT01000051 is a clinical study titled "Eltrombopag for Post Transplant Thrombocytopenia". The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.
What is the current status of trial NCT01000051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-02-17. Estimated completion is 2018-04-04.
What conditions does trial NCT01000051 study?
This clinical trial studies the following conditions: Thrombocytopenia.
What interventions are being tested in trial NCT01000051?
The interventions under investigation include: Placebo (DRUG), Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01000051?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01000051 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
COMPLETED · Phase 2
-
Daclizumab to Treat Chronic Immune Thrombocytopenia
COMPLETED · Phase 2
-
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.